Pembrolizumab
3475-593
Approved small_molecule completed
Quick answer
Pembrolizumab for Carcinoma, Non-Small-Cell Lung is a Approved program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Carcinoma, Non-Small-Cell Lung
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed